Effect of MetS* on Cognitive Performance and Physical Activity (Metabolic Syndrome)

Istanbul University - Cerrahpasa (IUC)

Status: Enrolling

Conditions: Metabolic Syndrome

Treatments: Other: assessment of cognitive performance

Study type: Observational

Funder types: Other

Identifiers

NCT05702437

3274238910

Details and patient eligibility

About

Metabolic syndrome (MetS) increases the risk of developing diabetes and cardiovascular disease risk factors that are linked with each other, which is a metabolic dysfunction, which contains a combination of multiple.

It is known that METS plays a role in the development of many diseases such as cardiovascular diseases, stroke, cancer, Alzheimer's. Studies have revealed that neuroinflammation, oxidative stress, abnormal lipid metabolism and impaired vascularization, which play a role in the pathogenesis of MetS, affect the structure of the brain and cognition. Atherosclerosis of the carotid artery, increased brain atrophy and white matter damage are potential explanatory mechanisms that lead to an impact on cognitive skills in patients with MetS. In addition, the existence of MetS components such as obesity, diabetes, hypertension alone also negatively affects cognitive functions, and the level of cognitive influence also increases as the number of components an individual has increases.

The literature reports that learning, executive functions, processing speed, attention/working memory and global cognitive functions are affected in individuals with MetS, but no consensus has been reached on this issue. Some studies say that MetS causes a significant decrease in cognitive functions, while some studies indicate that this difference is not significant.

The aim of our study is to proof the relationship between MetS and cognitive functions with metabolic syndrome components.

H1:There is a relationship between the MetS and cognitive functions.

Full description

Voluntary participants who have been diagnosed with MetS and agreed to voluntary health subjects will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into two groups. There will be individuals diagnosed with MetS in the intervention group and healthy individuals who do not have any problems in the control group.

Enrollment: 82 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• being between the ages of 18-50
• Having been educated for at least 5 years and know how to read and write
• Having been diagnosed with MetS by meeting 3 of the NCEP-ATP III criteria (for participants in the MetS Group)
• To have a biochemistry test performed within the last 6 months (for the Healthy Group)
• Not having any MetS components (For the Healthy Group)

Exclusion criteria

• Having any neurological, psychiatric and psychological diseases that may affect cognitive status
• Taking antipsychiatric medication
• The presence of any visual-auditory intellectual disability
• Having undergone bariatric surgery

Trial design

82 participants in 2 patient groups

MetS Group

Description:

it consists of volunteer participants diagnosed with MetS between the ages of 18 and 50. All assessments will be applied to the participants by two different researchers at the same time.

Treatment:

Other: assessment of cognitive performance

Control Group

Description:

it will consist of healthy individuals aged 18-50 who do not have any health problems and have volunteered to participate in the study who have undergone a health check within the last 6 months.

Treatment:

Other: assessment of cognitive performance